Overview

Study of Self or Clinic Administration of DepoProvera

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Depot medroxyprogesterone acetate (DepoProvera) is an acceptable form of contraception for many women. However, difficulty in access may cause many women to discontinue use, often without the use of another effective method of contraception, thereby leaving them vulnerable to unintended pregnancy. This study will randomly assign women who present for contraceptive services to two groups: self or clinic administered SC DMPA. The participants will be followed for one year to compare continuation rates, acceptability, cost effectiveness, evidence of skin changes, and need for continued support between the two groups.
Phase:
N/A
Details
Lead Sponsor:
Carolyn L. Westhoff
Collaborators:
Family Planning Fellowship
Pfizer
Treatments:
Medroxyprogesterone
Medroxyprogesterone Acetate